肝癌导向治疗的实验与临床研究  

TARGETING THERAPY OF HEPATOCELLULAR CARCINOMA——EXPERIMENTAL AND CLINICAL STUDIES

作　　者：汤钊猷[1] 刘康达[1] 范桢[1] 陆继珍[1] 张玉蛟 侯镇 包炎明[1] 周东 汤文英[1] 夏晓玲[1] 杨榕 余竹元[1] 林芷英[1] 马曾辰[1] 周信达[1] 余业勤[1] 杨秉辉[1] 赵惠扬[2] 袁爱娜[2] 周以国 

机构地区：[1]上海医科大学肝癌研究所 [2]上海医科大学核医学研究所 [3]上海医科大学药学院放射药学

出　　处：《肿瘤》1990年第6期241-245,共5页Tumor

摘　　要：原发性肝癌导向治疗研究在肿瘤导向研究中具有重要地位。肝癌是导向治疗进入临床试验的较早对象,积累的临床经验最多,探索的面亦较广。文献中所用“载体”除抗铁蛋白抗体外,还有抗甲胎蛋白抗体,抗人肝癌抗体,抗癌胚抗原抗体,抗乙型肝炎表面抗原抗体以及碘油等。所用“弹头”目前仍以放射性核素为主。Experimental and clinical studies on targeting therapy of hepatocellular carcinoma(HCC) during 1983--1990 were reported. In vitro and in, vivo comparison was madeamong 11 carriers including ferritin polyclonal antibody (PAb), H subunit ferritinmonoclonal antibody (MAb), L subunit ferritin MAb, anti HCC MAb, AFP MAb,AFP PAb, PMT, EDDA, Rhodamine 6GDN, Lipiodol, etc. Radioimmunoimaging bothin nude mice bearing HCO xenografts and HCC patients showed tumor targeting using131-I ferritin PAb or 131--I anti HCC MAb. Radioimmunotherapy using 131--I ferritinPAb was done in 41 patients with unresectable HCC, second stage resection was perform-ed in 13 out of the 41 patients after marked shrinkage of tumor. anti-antibody was notdetected when antibody was administered intraarterially. Sequential resection was alsosuccess in 11 out of the 34 patients after 131--I lipiodol treatment. Radioimmunoimagingdemonstrated that 131-I ferritin PAb seemed not inferior to that of 131-I anti HCCMAb. Thus, 131--I ferritin PAb and 131-I lipiodol might be modality of choice forcytoreduction, however, sequential resection was needed for irradicate residual cancercells.

关 键 词：肝癌 导向治疗 抗体 载体 临床实验 

分 类 号：R735.705[医药卫生—肿瘤]